RLMD - Relmada Therapeutics Inc Stock Price, Fair Value and News

$4.03-0.01 (-0.25%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

RLMD Price Action

Last 7 days

-3.8%

Last 30 days

83.2%

Last 90 days

194.2%

Trailing 12 Months

45.5%

RLMD RSI Chart

RLMD Valuation

Market Cap

295.5M

Price/Earnings (Trailing)

-5.26

Price/Sales (Trailing)

46.26

Price/Free Cashflow

-7.39

RLMD Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

RLMD Fundamentals

RLMD Revenue

Revenue (TTM)

6.2M

RLMD Earnings

Earnings (TTM)

-56.2M

Earnings Growth (Yr)

53.55%

Earnings Growth (Qtr)

-2.28%

RLMD Profitability

Return on Equity

-593.46%

Return on Assets

-377.61%

Free Cashflow Yield

-13.53%

RLMD Investor Care

Shares Dilution (1Y)

143.03%

Diluted EPS (TTM)

-1.8

RLMD Alerts

4 major insider buys recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	0	0	0	6.2M
2020	0	0	818.3K	0
2019	0	0	0	0
2018	0	0	0	0
2017	0	96.4K	0	0
2014	66.0K	0	0	0
2013	6.5K	5.8K	5.1K	35.6K
2012	0	0	7.9K	7.2K

Get all data in R, Python etc through our Historical Stock Data APIs

About Relmada Therapeutics Inc

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

CEO	Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD
WEBSITE	relmada.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	14

Relmada Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Relmada Therapeutics Inc? What does RLMD stand for in stocks?

RLMD is the stock ticker symbol of Relmada Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Relmada Therapeutics Inc (RLMD)?

As of Wed Dec 03 2025, market cap of Relmada Therapeutics Inc is 295.53 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RLMD stock?

You can check RLMD's fair value in chart for subscribers.

Is Relmada Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether RLMD is over valued or under valued. Whether Relmada Therapeutics Inc is cheap or expensive depends on the assumptions which impact Relmada Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RLMD.

What is Relmada Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, RLMD's PE ratio (Price to Earnings) is -5.26 and Price to Sales (PS) ratio is 46.26. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RLMD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Relmada Therapeutics Inc's stock?

In the past 10 years, Relmada Therapeutics Inc has provided -0.092 (multiply by 100 for percentage) rate of return.